Christopher Langmead

Dr

20012020
If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

  • Head, Servier Program in Drug Discovery
  • Faculty of Pharmacy and Pharmaceutical Sciences
  • Monash Institute of Pharmaceutical Sciences

Chris Langmead has a strong interest in drug discovery, having spent 15 years working in the pharmaceutical and biotech industry in the UK, where he led project teams to discover four pre-clinical candidate drugs and managed collaborations with academic labs and other pharmaceutical companies.

In 2012 he joined MIPS to head up a drug discovery program in collaboration with Servier Laboratories, France. He is particularly interested in GPCRs as drug targets in neurodegenerative and psychiatric disorders, but also has interest in structure-function of GPCRs and analytical receptor pharmacology, with particular reference to allosteric interactions.

In 2012 he joined MIPS to head up a drug discovery program in collaboration with Servier Laboratories, France. He is particularly interested in GPCRs as drug targets in neurodegenerative and psychiatric disorders, but also has interest in structure-function of GPCRs and analytical receptor pharmacology, with particular reference to allosteric interactions.

Servier Program in Drug Discovery

In 2012, the Monash Institute of Pharmaceutical Sciences (MIPS) entered into a collaborative drug discovery research agreement with Les Laboratoires Servier, a leading European pharmaceutical company (http://tinyurl.com/brrztb4).

The collaboration makes use of MIPS' acknowledged world-leading capability in the identification of novel GPCR targets, in the understanding of GPCR functional biology and in the design of new chemical entities to modulate GPCR activity. MIPS has developed GPCR expertise comprising technology, research facilities and world leading scientists that enable it to conduct fundamental research, drug discovery and preclinical drug development activities on GPCR targets with therapeutic potential.

Monash teaching commitment

  • Lectures to 3rd year BPharmSci students in the Faculty of Pharmacy and Pharmaceutical Sciences
  • Supervision of Honours students in Drug Discovery Biology

Research interests

  • GPCR target validation, hit identification and lead optimisation
  • CNS drug discovery
  • Allosteric modulation of GPCRs
  • Molecular and analytical pharmacology

Keywords

  • G protein-coupled receptors
  • drug discovery
  • hit identification
  • high throughput screening
  • muscarinic receptors
  • neuropharmacology
  • analytical pharmacology
  • allosteric modulation
  • structure-function
  • target validation
  • hit-to-lead
  • lead optimisation
  • psychiatric disorders
  • cognitive disorders

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2016 2020

Research Output 2001 2019

Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H3 receptor antagonists

Riddy, D. M., Cook, A. E., Shackleford, D. M., Pierce, T. L., Mocaer, E., Mannoury la Cour, C., Sors, A., Charman, W. N., Summers, R. J., Sexton, P. M., Christopoulos, A. & Langmead, C. J., 1 Jan 2019, In : Neuropharmacology. 144, p. 244-255 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File

Bitopic binding mode of an M1 muscarinic acetylcholine receptor agonist associated with adverse clinical trial outcomes S

Bradley, S. J., Molloy, C., Bundgaard, C., Mogg, A. J., Thompson, K. J., Dwomoh, L., Sanger, H. E., Crabtree, M. D., Brooke, S. M., Sexton, P. M., Felder, C. C., Christopoulos, A., Broad, L. M., Tobin, A. B. & Langmead, C. J., 1 Jun 2018, In : Molecular Pharmacology. 93, 6, p. 645-656 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File

Comparative genotypic and phenotypic analysis of human peripheral blood monocytes and surrogate monocyte-like cell lines commonly used in metabolic disease research

Riddy, D. M., Goy, E., Delerive, P., Summers, R. J. & Langmead, C. J., 1 May 2018, In : PLoS ONE. 13, 5, 19 p., e0197177.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File

Discovery and Optimization of Potent and CNS Penetrant M5-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold

Bender, A. M., Cho, H. P., Nance, K. D., Lingenfelter, K. S., Luscombe, V. B., Gentry, P. R., Voigtritter, K., Berizzi, A. E., Sexton, P. M., Langmead, C. J., Christopoulos, A., Locuson, C. W., Bridges, T. M., Chang, S., O'Neill, J. C., Zhan, X., Niswender, C. M., Jones, C. K., Conn, P. J. & Lindsley, C. W., 18 Jul 2018, In : ACS Chemical Neuroscience. 9, 7, p. 1572-1581 10 p.

Research output: Contribution to journalArticleResearchpeer-review

Divergent effects of strontium and calcium-sensing receptor positive allosteric modulators (calcimimetics) on human osteoclast activity

Diepenhorst, N. A., Leach, K., Keller, A. N., Rueda, P., Cook, A. E., Pierce, T. L., Nowell, C., Pastoureau, P., Sabatini, M., Summers, R. J., Charman, W. N., Sexton, P. M., Christopoulos, A. & Langmead, C. J., 1 Nov 2018, In : British Journal of Pharmacology. 175, 21, p. 4095-4108 14 p.

Research output: Contribution to journalArticleResearchpeer-review